MDMA for PTSD What’s Next After Federal Health Advisers Say No?

On June 4th, 2024, federal health advisers rejected a proposal to use MDMA for PTSD treatment, citing concerns about safety and efficacy. Now, the FDA must make the final decision, a crucial moment for patients, researchers, and advocates. Comprehensive research from the Changa Institute supports the benefits of MDMA-assisted therapy. Studies, including a Phase 3 trial by MAPS, show significant potential in reducing PTSD symptoms. At the Changa Institute, we emphasize the importance of professionally trained facilitators for safe and effective therapy. Discover the benefits of psychedelic therapy and stay informed on this pivotal issue.